Cargando…

Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy

Dendritic cells (DCs) are essential antigen-presenting cells for the initiation of cytotoxic T-cell responses and therefore attractive targets for cancer immunotherapy. We have developed an integration-deficient lentiviral vector termed ID-VP02 that is designed to deliver antigen-encoding nucleic ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Odegard, Jared M., Kelley-Clarke, Brenna, Tareen, Semih U., Campbell, David J., Flynn, Patrick A., Nicolai, Christopher J., Slough, Megan M., Vin, Chintan D., McGowan, Patrick J., Nelson, Lisa T., ter Meulen, Jan, Dubensky, Thomas W., Robbins, Scott H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Basic Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323576/ https://www.ncbi.nlm.nih.gov/pubmed/25658613 http://dx.doi.org/10.1097/CJI.0000000000000067

Ejemplares similares

A Rev-Independent gag/pol Eliminates Detectable psi-gag Recombination in Lentiviral Vectors
por: Tareen, Semih U., et al.
Publicado: (2013)

Design of a titering assay for lentiviral vectors utilizing direct extraction of DNA from transduced cells in microtiter plates
por: Murphy, Michele E, et al.
Publicado: (2016)

Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors
por: Farley, Daniel C, et al.
Publicado: (2015)

A "prime-pull" immunotherapy approach using a lentiviral vector and intratumoral TLR4 agonist redirects cytotoxic T cells
por: Albershardt, Tina C, et al.
Publicado: (2014)

LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response
por: Albershardt, Tina Chang, et al.
Publicado: (2016)

2002 Pioneer in NeuroVirology lecture
por: Wigdahl, B., et al.
Publicado: (2014)

Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing
por: Cambon, Karine, et al.
Publicado: (2017)

The Comparative Value of Feline Virology Research: Can Findings from the Feline Lentiviral Vaccine Be Translated to Humans?
por: Hosie, Margaret J., et al.
Publicado: (2017)

Checkpoint inhibitors synergize with therapeutic platforms, ZVex™ and GLAAS™ by enhancing lentiviral vector-induced tumor-specific immunity and adjuvant-mediated anti-tumor efficacy
por: Albershardt, Tina C, et al.
Publicado: (2015)

Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors
por: Matsumoto, Hiroshi, et al.
Publicado: (2010)

Intratumoral injections of G100 (synthetic TLR4 agonist) increase trafficking of lentiviral vector-induced antigen-specific CD8 T cells to the tumor microenvironment
por: Albershardt, Tina C, et al.
Publicado: (2015)

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
por: Michels, Kathryn R, et al.
Publicado: (2023)

HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells
por: Wee, Edmund G., et al.
Publicado: (2017)

Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency
por: Poletti, Valentina, et al.
Publicado: (2018)

Preclinical Proof-of-Concept, Analytical Development, and Commercial Scale Production of Lentiviral Vector in Adherent Cells
por: Leinonen, Hanna M., et al.
Publicado: (2019)

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
por: Nemirov, Kirill, et al.
Publicado: (2023)

Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory
por: Leleux, Jardin A., et al.
Publicado: (2021)

Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
por: Negre, Olivier, et al.
Publicado: (2015)

Preclinical safety and efficacy of lentiviral-mediated gene therapy for leukocyte adhesion deficiency type I
por: Mesa-Núñez, Cristina, et al.
Publicado: (2022)

Lentiviral Vector Gene Transfer to Porcine Airways
por: Sinn, Patrick L, et al.
Publicado: (2012)

Preclinical Safety and Efficacy of Human CD34(+) Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome
por: Scaramuzza, Samantha, et al.
Publicado: (2013)

Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice
por: Gallinaro, Alessandra, et al.
Publicado: (2020)

Epigenomic Mechanisms of Early Adversity and HPA Dysfunction: Considerations for PTSD Research
por: McGowan, Patrick O.
Publicado: (2013)

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient
por: Pollack, Seth M., et al.
Publicado: (2017)

Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome
por: Catucci, Marco, et al.
Publicado: (2011)

Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models
por: Ku, Min-Wen, et al.
Publicado: (2021)

Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment
por: Navarro, Susana, et al.
Publicado: (2021)

The Victoria Assistive Devices and Coach (VADAC) study
por: McGowan, Patrick, et al.
Publicado: (2022)

Virology
por: Boland, G. J.
Publicado: (2017)

The stability of envelope-pseudotyped lentiviral vectors
por: Dautzenberg, Iris J. C., et al.
Publicado: (2020)

Virology
por: Kanki, Phyllis J., et al.
Publicado: (2005)

Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47(phox)-Deficient Chronic Granulomatous Disease
por: Schejtman, Andrea, et al.
Publicado: (2021)

Virologic failure and mortality in older ART initiators in a multisite Latin American and Caribbean Cohort
por: Carriquiry, Gabriela, et al.
Publicado: (2018)

Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report
por: Qian, Han-Zhu, et al.
Publicado: (2014)

Production of lentiviral vectors
por: Merten, Otto-Wilhelm, et al.
Publicado: (2016)

Lentiviral Vector Bioprocessing
por: Perry, Christopher, et al.
Publicado: (2021)

Lentiviral standards to determine the sensitivity of assays that quantify lentiviral vector copy numbers and genomic insertion sites in cells
por: Corre, Guillaume, et al.
Publicado: (2022)

Updating movement estimates for American black ducks (Anas rubripes)
por: Robinson, Orin J., et al.
Publicado: (2016)

Lentiviral-based anti-HIV therapeutic vaccine: design, preclinical studies and phaseI/II clinical trial preliminary results
por: Bauche, Cécile, et al.
Publicado: (2014)

Envelope Determinants of Equine Lentiviral Vaccine Protection
por: Craigo, Jodi K., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_72vq42pq68fj5aks5vug6jbjrj